|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_advisor
|
leading oncologists
|
|
gptkbp:acquired_by
|
gptkb:Abb_Vie
|
|
gptkbp:acquisition
|
$5.8 billion
|
|
gptkbp:acquisition_year
|
gptkb:2016
|
|
gptkbp:awards
|
entrepreneurial awards
biotechnology innovation awards
|
|
gptkbp:business_model
|
clinical trials
biopharmaceutical development
research-driven
commercialization of drugs
|
|
gptkbp:ceo
|
gptkb:Dr._David_A._Hyman
|
|
gptkbp:clinical_trial
|
ongoing
Phase 2
ongoing trials
Rova-T clinical trials
|
|
gptkbp:collaborations
|
academic institutions
pharmaceutical companies
academic partnerships
research hospitals
|
|
gptkbp:community_engagement
|
health initiatives
patient advocacy groups
healthcare organizations
cancer research foundations
|
|
gptkbp:focus
|
gptkb:cancer_treatment
|
|
gptkbp:focuses_on
|
cancer therapies
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founded_by
|
Abbie Smith
|
|
gptkbp:founder
|
gptkb:Dr._John_D._Mendelsohn
gptkb:John_Mc_Carty
|
|
gptkbp:future_plans
|
gptkb:expansion
|
|
gptkbp:grants
|
awarded
|
|
gptkbp:headcount
|
approximately 150
|
|
gptkbp:headquarters
|
gptkb:South_San_Francisco,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Stemcentrx
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
multiple
biotechnology patents
pharmaceutical patents
|
|
gptkbp:investment
|
gptkb:significant
gptkb:Sofinnova_Ventures
gptkb:Venrock
gptkb:Canaan_Partners
active
venture capital firms
The Column Group
|
|
gptkbp:investment_focus
|
gptkb:cancer_treatment
oncology
pharmaceutical market
biotechnology market
|
|
gptkbp:key_people
|
gptkb:Michael_A._Haller
gptkb:Dr._John_D._Mendelsohn
gptkb:David_M._Hyman
gptkb:John_Mc_Carty
|
|
gptkbp:leadership
|
experienced executives
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market_position
|
growing
|
|
gptkbp:marketing_strategy
|
targeted therapies
|
|
gptkbp:notable_products
|
Rova-T
|
|
gptkbp:number_of_employees
|
over 100
|
|
gptkbp:partnership
|
gptkb:Abb_Vie
research institutions
|
|
gptkbp:partnerships
|
various academic institutions
|
|
gptkbp:pipeline_products
|
various
|
|
gptkbp:product
|
advanced stages
|
|
gptkbp:product_type
|
biopharmaceuticals
therapeutics
|
|
gptkbp:publications
|
gptkb:conference
numerous
peer-reviewed journals
clinical research articles
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
FDA approval for Rova-T
|
|
gptkbp:research
|
stem cell research
|
|
gptkbp:research_and_development
|
cancer treatment innovations
|
|
gptkbp:research_areas
|
immuno-oncology
|
|
gptkbp:research_focus
|
stem cell biology
tumor microenvironment
solid tumors
small cell lung cancer
hematologic malignancies
|
|
gptkbp:services
|
drug development
|
|
gptkbp:strategic_goals
|
innovation in oncology
|
|
gptkbp:technology
|
targeted therapies
antibody-drug conjugates
|
|
gptkbp:treatment
|
promising
|
|
gptkbp:type
|
private company
|
|
gptkbp:type_of_business
|
strong
|
|
gptkbp:website
|
www.stemcentrx.com
|
|
gptkbp:year_established
|
gptkb:2010
|
|
gptkbp:bfsParent
|
gptkb:Abb_Vie
|
|
gptkbp:bfsLayer
|
4
|